Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor

Anders Bach, Bettina Hjelm Clausen, Lotte Kellemann Kristensen, Maria Gammelstrup Andersen, Ditte Gry Ellman, Pernille B. Lærkegaard Hansen, Henrik Hasseldam, Marc Heitz, Dennis Özcelik, Ellie J. Tuck, Maksym V. Kopanitsa, Seth G.N. Grant, Karin Lykke-Hartmann, Flemming F. Johansen, Kate Lykke Lambertsen*, Kristian Strømgaard

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-D-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.

Original languageEnglish
JournalNeuropharmacology
Volume150
Pages (from-to)100-111
ISSN0028-3908
DOIs
Publication statusPublished - 15. May 2019

Fingerprint

N-Methyl-D-Aspartate Receptors
Arterial Pressure
Fluorescence Polarization
Middle Cerebral Artery Infarction
Rodentia
postsynaptic density proteins
Clinical Trials
Pharmaceutical Preparations
Proteins
Tat-NR2B9c
Neuroprotection

Keywords

  • Dimeric inhibitor
  • Ischemic stroke
  • MAGUKs
  • Neuroprotection
  • PSD-95

Cite this

Bach, Anders ; Clausen, Bettina Hjelm ; Kristensen, Lotte Kellemann ; Andersen, Maria Gammelstrup ; Ellman, Ditte Gry ; Hansen, Pernille B. Lærkegaard ; Hasseldam, Henrik ; Heitz, Marc ; Özcelik, Dennis ; Tuck, Ellie J. ; Kopanitsa, Maksym V. ; Grant, Seth G.N. ; Lykke-Hartmann, Karin ; Johansen, Flemming F. ; Lambertsen, Kate Lykke ; Strømgaard, Kristian. / Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. In: Neuropharmacology. 2019 ; Vol. 150. pp. 100-111.
@article{abe33f523d84423fabf6c64f8568549f,
title = "Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor",
abstract = "Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-D-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.",
keywords = "Dimeric inhibitor, Ischemic stroke, MAGUKs, Neuroprotection, PSD-95",
author = "Anders Bach and Clausen, {Bettina Hjelm} and Kristensen, {Lotte Kellemann} and Andersen, {Maria Gammelstrup} and Ellman, {Ditte Gry} and Hansen, {Pernille B. L{\ae}rkegaard} and Henrik Hasseldam and Marc Heitz and Dennis {\"O}zcelik and Tuck, {Ellie J.} and Kopanitsa, {Maksym V.} and Grant, {Seth G.N.} and Karin Lykke-Hartmann and Johansen, {Flemming F.} and Lambertsen, {Kate Lykke} and Kristian Str{\o}mgaard",
year = "2019",
month = "5",
day = "15",
doi = "10.1016/j.neuropharm.2019.02.035",
language = "English",
volume = "150",
pages = "100--111",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Pergamon Press",

}

Bach, A, Clausen, BH, Kristensen, LK, Andersen, MG, Ellman, DG, Hansen, PBL, Hasseldam, H, Heitz, M, Özcelik, D, Tuck, EJ, Kopanitsa, MV, Grant, SGN, Lykke-Hartmann, K, Johansen, FF, Lambertsen, KL & Strømgaard, K 2019, 'Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor', Neuropharmacology, vol. 150, pp. 100-111. https://doi.org/10.1016/j.neuropharm.2019.02.035

Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. / Bach, Anders; Clausen, Bettina Hjelm; Kristensen, Lotte Kellemann; Andersen, Maria Gammelstrup; Ellman, Ditte Gry; Hansen, Pernille B. Lærkegaard; Hasseldam, Henrik; Heitz, Marc; Özcelik, Dennis; Tuck, Ellie J.; Kopanitsa, Maksym V.; Grant, Seth G.N.; Lykke-Hartmann, Karin; Johansen, Flemming F.; Lambertsen, Kate Lykke; Strømgaard, Kristian.

In: Neuropharmacology, Vol. 150, 15.05.2019, p. 100-111.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor

AU - Bach, Anders

AU - Clausen, Bettina Hjelm

AU - Kristensen, Lotte Kellemann

AU - Andersen, Maria Gammelstrup

AU - Ellman, Ditte Gry

AU - Hansen, Pernille B. Lærkegaard

AU - Hasseldam, Henrik

AU - Heitz, Marc

AU - Özcelik, Dennis

AU - Tuck, Ellie J.

AU - Kopanitsa, Maksym V.

AU - Grant, Seth G.N.

AU - Lykke-Hartmann, Karin

AU - Johansen, Flemming F.

AU - Lambertsen, Kate Lykke

AU - Strømgaard, Kristian

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-D-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.

AB - Inhibition of postsynaptic density protein-95 (PSD-95) decouples N-methyl-D-aspartate (NMDA) receptor downstream signaling and results in neuroprotection after focal cerebral ischemia. We have previously developed UCCB01-144, a dimeric PSD-95 inhibitor, which binds PSD-95 with high affinity and is neuroprotective in experimental stroke. Here, we investigate the selectivity, efficacy and toxicity of UCCB01-144 and compare with the monomeric drug candidate Tat-NR2B9c. Fluorescence polarization using purified proteins and pull-downs of mouse brain lysates showed that UCCB01-144 potently binds all four PSD-95-like membrane-associated guanylate kinases (MAGUKs). In addition, UCCB01-144 affected NMDA receptor signaling pathways in ischemic brain tissue. UCCB01-144 reduced infarct size in young and aged male mice at various doses when administered 30 min after permanent middle cerebral artery occlusion, but UCCB01-144 was not effective in young male mice when administered 1 h post-ischemia or in female mice. Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. Overall, UCCB01-144 is a potent MAGUK inhibitor that reduces neurotoxic PSD-95-mediated signaling and improves neuronal survival following focal brain ischemia in rodents under various conditions and without causing cardiovascular side effects, which encourages further studies towards clinical stroke trials.

KW - Dimeric inhibitor

KW - Ischemic stroke

KW - MAGUKs

KW - Neuroprotection

KW - PSD-95

U2 - 10.1016/j.neuropharm.2019.02.035

DO - 10.1016/j.neuropharm.2019.02.035

M3 - Journal article

VL - 150

SP - 100

EP - 111

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -